Recombinant Human GM-CSF and Azidothymidine for HIV Infection and Leukopenia
Zidovudine
+ Sargramostim
Blood-Borne Infections+18
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
This study focuses on patients with HIV infection and leukopenia, a condition characterized by low white blood cell count. The main goal is to evaluate the safety of sargramostim, also known as recombinant human GM-CSF, when given repeatedly to these patients. The study also aims to understand if GM-CSF can prevent some or all of the hematologic toxicity, or blood-related side effects, associated with another HIV medication, zidovudine (AZT), in patients who already have leukopenia. Additionally, the study explores any potential clinical and/or virologic benefits of administering alternating weeks of GM-CSF and AZT to patients with symptomatic HIV infection who have a history of Pneumocystis carinii pneumonia (PCP) or a low CD4 lymphocyte count.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location